In 502 adults with moderate-to-severe plaque psoriasis, biosimilar BAT2306 was equivalent to reference secukinumab for percentage PASI change at week 8 (difference 1·549) and week 12 (−0·349), within all regulatory margins; safety and immunogenicity were comparable.
RCTn = 502
Chen et al. Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial